克服5-氟尿嘧啶与卡培他滨精准给药实施障碍
本文讨论氟尿嘧啶类(5FU和卡培他滨)传统按体表面积给药不精确,证据显示DPD酶活性检测和静脉5FU药代动力学指导给药可减少毒性并改善结局,但临床未统一采用;文章识别实施障碍并提出解决方案。
要点
- 传统体表面积给药不能精确确定氟尿嘧啶类最佳剂量。
- DPD酶活性检测和静脉5FU药代动力学指导给药有证据支持。
- 精准给药在临床实践中尚未被统一采用。
核心结论
- 氟尿嘧啶类精准给药有证据支持但临床实施存在障碍,需识别并解决以推动实践改变。
研究设计与样本
- 本文为综述/观点性文章,识别并讨论5FU和卡培他滨精准给药实施的障碍及可能解决方案。
主要发现
- 按体表面积给药被证明是确定氟尿嘧啶类最佳剂量的不精确方法。
- DPD酶活性检测和静脉5FU药代动力学指导给药可减少毒性并改善患者结局。
临床怎么用
- 临床应考虑采用DPD酶活性检测和静脉5FU药代动力学指导给药等精准给药方法。
- 需识别并克服实施精准给药的障碍以改变临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in targeted cancer therapy, the fluoropyrimidines 5-fluorouracil (5FU) and capecitabine continue to play an important role in oncology. Historically, dosing of these drugs has been based on body surface area. This approach has been demonstrated to be an imprecise way to determine the optimal dose for a patient. Evidence in the literature has demonstrated that precision dosing approaches, such as DPD enzyme activity testing and, in the case of intravenous 5FU, pharmacokinetic-guided dosing, can reduce toxicity and yield better patient outcomes. However, despite the evidence, there has not been uniform adoption of these approaches in the clinical setting. When a drug such as 5FU has been used clinically for many decades, it may be difficult to change clinical practice. With the aim of facilitating change of practice, issues and barriers to implementing precision dosing approaches for 5FU and capecitabine are identified and discussed with possible solutions proposed.
引用
- Schneider JJ, Galettis P, Martin JH, et al. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. Br J Clin Pharmacol. 2021. PMID: 33386659. doi:10.1111/bcp.14723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。